Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph early_phase_1
1
20%
Ph phase_1
2
40%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Terminated2
Recruiting1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 12 (50.0%)
Phase 21 (25.0%)

Trials by Status

recruiting120%
unknown120%
terminated240%
completed120%

Recent Activity

1 active trials
Showing 5 of 5
terminatedphase_2

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

NCT05588609
recruiting

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

NCT06473259
terminatedphase_1

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

NCT05405439
unknownearly_phase_1

Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults

NCT04735913
completedphase_1

A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers

NCT01362764

Clinical Trials (5)

Showing 5 of 5 trials
NCT05588609Phase 2

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Terminated
NCT06473259

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Recruiting
NCT05405439Phase 1

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Terminated
NCT04735913Early Phase 1

Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults

Unknown
NCT01362764Phase 1

A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5